BioCentury | Apr 29, 2020
Product Development

Highlights from AACR’s first annual virtual meeting show mixed results for I/O combos, promise for new targets, modalities

Immuno-oncology combinations showed mixed results at the first of two virtual annual meetings this year of the American Association for Cancer Research, with PD-L1 inhibitor Tecentriq atezolizumab reporting two negative readouts and uninspiring monotherapy data...
BioCentury | Oct 19, 2019
Product Development

Tracking the rise and fall of next-generation checkpoint targets for cancer

As the race continues for the next big checkpoint target after PD-1, three candidates are pulling ahead. BioCentury has been following the rise and fall of clinical programs against promising checkpoint proteins since the field...
BC Week In Review | Mar 8, 2019
Company News

Compugen cuts workforce by 35%

Compugen will reduce headcount by 35 (35%), with cuts coming primarily from R&D. Compugen Ltd. (NASDAQ:CGEN) said the moves will extend its cash runway through mid-2020 and allow it to fund an expansion study of...
BC Week In Review | Oct 12, 2018
Company News

Compugen partners with BMS for Phase I combo trial of its first-in-class checkpoint inhibitor

Compugen Ltd. (NASDAQ:CGEN) partnered with Bristol-Myers Squibb Co. (NYSE:BMY) to evaluate its first-in-class mAb COM701 plus BMS's anti-PD-1 mAb Opdivo nivolumab for advanced solid tumors. COM701 targets new checkpoint target poliovirus receptor related immunoglobulin domain...
BC Innovations | Aug 24, 2018
Targets & Mechanisms

Computing checkpoints

After 25 years as a discovery company, Compugen Ltd. is about to enter the clinic for the first time with a first-in-class mAb against a new checkpoint target. The target’s expression on adaptive immune cells,...
Items per page:
1 - 5 of 5